AIM: to study the molecular mechanisms underlying α-tocopheryl succinate (α-TOS)-induced apoptosis in erbB2-positive breast cancer cells and to determine whether α-TOS and the human recombinant TNF-related apoptosis-inducing ligand (hrTRAIL) act synergically to induce cell death of erbB2-expressing breast cancer cells. METHODS: the annexin V binding method was used to measure apoptosis induced by α-TOS and/or hrTRAIL. RT-PCR and Western blotting were performed to detect gene and protein expression. A colorimetric assay was performed to detect caspase activity. The TransAM(TM) NF-κB p65 kit was used to assess NF-κB activation. RESULTS: α-TOS (100 μmol/L) significantly inhibited NF-κB nuclear translocation in erbB2-expressing breast cancer cells; this inhibition is expected to result in the inactivation of NF-κB. α-TOS (50 and 100 μmol/L) inhibited the expression of Flice-like inhibitory protein (FLIP) and cellular inhibitor of apoptosis protein 1 (c-IAP1) in erbB2-positive cells. α-TOS (100 μmol/L) inhibited Akt activation and augmented the activity of caspase 3 and caspase 8 in breast cancer cells expressing erbB2. α-TOS (50 μmol/L) and hrTRAIL (30 mg/mL) acted synergically to induce apoptosis in breast cancer cells. α-TOS also decreased the hrTRAIL-induced transient activation of NF-κB . CONCLUSION: our results suggest that α-TOS mediates the apoptosis of erbB2-positive breast cancer cells and acts synergically with hrTRAIL via the NF-κB pathway.
AIM: to study the molecular mechanisms underlying α-tocopheryl succinate (α-TOS)-induced apoptosis in erbB2-positive breast cancer cells and to determine whether α-TOS and the human recombinant TNF-related apoptosis-inducing ligand (hrTRAIL) act synergically to induce cell death of erbB2-expressing breast cancer cells. METHODS: the annexin V binding method was used to measure apoptosis induced by α-TOS and/or hrTRAIL. RT-PCR and Western blotting were performed to detect gene and protein expression. A colorimetric assay was performed to detect caspase activity. The TransAM(TM) NF-κB p65 kit was used to assess NF-κB activation. RESULTS: α-TOS (100 μmol/L) significantly inhibited NF-κB nuclear translocation in erbB2-expressing breast cancer cells; this inhibition is expected to result in the inactivation of NF-κB. α-TOS (50 and 100 μmol/L) inhibited the expression of Flice-like inhibitory protein (FLIP) and cellular inhibitor of apoptosis protein 1 (c-IAP1) in erbB2-positive cells. α-TOS (100 μmol/L) inhibited Akt activation and augmented the activity of caspase 3 and caspase 8 in breast cancer cells expressing erbB2. α-TOS (50 μmol/L) and hrTRAIL (30 mg/mL) acted synergically to induce apoptosis in breast cancer cells. α-TOS also decreased the hrTRAIL-induced transient activation of NF-κB . CONCLUSION: our results suggest that α-TOS mediates the apoptosis of erbB2-positive breast cancer cells and acts synergically with hrTRAIL via the NF-κB pathway.
Authors: F Chang; J T Lee; P M Navolanic; L S Steelman; J G Shelton; W L Blalock; R A Franklin; J A McCubrey Journal: Leukemia Date: 2003-03 Impact factor: 11.528
Authors: Tobias Weber; Helge Dalen; Ladislav Andera; Anne Nègre-Salvayre; Nathalie Augé; Martin Sticha; Ana Lloret; Alexei Terman; Paul K Witting; Masahiro Higuchi; Magdalena Plasilova; Jan Zivny; Nina Gellert; Christian Weber; Jiri Neuzil Journal: Biochemistry Date: 2003-04-15 Impact factor: 3.162
Authors: Tobias Weber; Min Lu; Ladislav Andera; Harald Lahm; Nina Gellert; Marc W Fariss; Vladimir Korinek; Wolfgang Sattler; David S Ucker; Alexei Terman; Andreas Schröder; Wolfgang Erl; Ulf T Brunk; Robert J Coffey; Christian Weber; Jiri Neuzil Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Jiri Neuzil; Marco Tomasetti; Albert S Mellick; Renata Alleva; Brian A Salvatore; Marc Birringer; Marc W Fariss Journal: Curr Cancer Drug Targets Date: 2004-06 Impact factor: 3.428